Taffix® Laboratory studies
Fluorescence measurement in cells treated with test solutions. GFP lentivirus was used based on its ability to insert a GFP fluorescent gene into infected cells thus enabling the identification of virus-infected cells.
Taffix® blocks SARS-CoV-2 (COVID-19 disease) virus cells infection
Efficacy of Taffix® against COVID-19 - Plaque assay: virus infectivity
Based on this assay, about 4000 virus particles was recovered from the untreated well,
whereas no virus was detected on the gel-treated.
Ten (10) ul of SARS-CoV-2, Hong Kong/VM20, at a clinical disease state concentration of 10^6, was inoculated on to untreated and Taffix® gel-treated filters. Taffix® amount was equivalent to a clinical dose of 1 puff. The eluting virus solution was tested for RNA level by PCR and for virus infectivity by plaque assay on live cells. The study was performed by Dr. Barbara Mann, Associate Professor, Medicine: Infectious Diseases and International Health, University of Virginia, USA
Efficacy of Taffix® against COVID-19 - Quantification of virus RNA - 99.9% blockage
The gel layer produced by Taffix® powder after administration of a clinically equivalent amount, effectively blocked SARS-CoV-2 virus, as demonstrated by reduction in virus RNA equivalent to 4 log reduction in virus count. Taffix® also protected more than 99% of cells from infection by live SARS-CoV-2 virus.
Taffix® effectiveness against new variants of SARS-Cov-2 (Alpha, Beta and Delta)
Real Life Survey
Low pH Hypromellose (Taffix®) nasal powder spray reduced SARS-CoV-2 infection rate post mass-gathering event at a highly endemic community: An observational prospective open label user survey
Klang Shmuel, Mann Barbara , Megiddo Dalia, Lapidot Tair, Napartek Yaakov